LENZ Therapeutics (LENZ) EBT (2020 - 2026)
LENZ Therapeutics (LENZ) posted quarterly EBT of -$42.2 million for Q1 2026, down 165.34% year-over-year from $64.6 million in Q1 2025, and down 17.59% quarter-over-quarter from -$35.9 million in Q4 2025.
LENZ Therapeutics (LENZ) EBT (2020 - 2026) Analysis & Trends
LENZ Therapeutics (LENZ) has reported EBT for 7 consecutive years, with -$42.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, EBT fell 165.34% year-over-year to -$42.2 million; the TTM figure through Mar 2026 stood at -$109.2 million (down 122.76% YoY), while the FY2025 annual figure was -$81.6 million, down 64.01% from the prior year.
- EBT fell to -$42.2 million in Q1 2026 per LENZ's latest filing, from -$35.9 million in the prior quarter.
- Across five years, EBT topped out at -$10.2 million in Q3 2024 and bottomed at -$636.4 million in Q2 2022.
- Historically, EBT has averaged -$61.2 million across 5 years, with a median of -$18.2 million in 2023.
- Annual changes were most pronounced in 2022 — EBT plunged 387.6% — and 2023, when it jumped 92.18%.
- LENZ Therapeutics' EBT stood at -$28.3 million in 2022, then surged by 35.87% to -$18.2 million in 2023, then jumped by 30.4% to -$12.7 million in 2024, then tumbled by 183.72% to -$35.9 million in 2025, then slipped by 17.59% to -$42.2 million in 2026.
- Business Quant data shows LENZ's EBT at -$42.2 million in Q1 2026, -$35.9 million in Q4 2025, and -$16.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 541.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -767.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 312.46 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 177.81 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -11.37 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 81.49 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -264.70 Mn |
| 10 | LENZ Therapeutics | 146.20 Mn | 146.20 Mn | 5.21 Mn | -31.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -31.92 Mn |
| Mar 31, 2026 | -42.21 Mn |
| Dec 31, 2025 | -35.89 Mn |
| Sep 30, 2025 | -16.70 Mn |
| Jun 30, 2025 | -14.41 Mn |
| Mar 31, 2025 | -15.91 Mn |
| Dec 31, 2024 | -12.65 Mn |
| Sep 30, 2024 | -10.22 Mn |
| Jun 30, 2024 | -10.25 Mn |
| Mar 31, 2024 | -16.14 Mn |
| Dec 31, 2023 | -18.18 Mn |
| Sep 30, 2023 | -53.23 Mn |
| Jun 30, 2023 | -49.79 Mn |
| Mar 31, 2023 | -17.43 Mn |
| Dec 31, 2022 | -28.35 Mn |
| Sep 30, 2022 | -34.23 Mn |
| Jun 30, 2022 | -636.45 Mn |
| Mar 31, 2022 | -27.58 Mn |
| Dec 31, 2021 | -20.94 Mn |
| Sep 30, 2021 | -54.99 Mn |